November 20, 2023

New Ways to Battle Cancer: Q&A With William Ho, CEO of IN8bio

Pharmaceutical Executive: Can you provide some background on gamma-delta T-Cells?
William Ho: I’ve been in the biotech industry for over 22 years, and much of that was spent on the Wall Street side (investor banking, equity research, and as an investor). I co-founded the company together in 2016, and today we’re one of the leading companies developing gamma-delta T-Cells in oncology as a cellular therapy. Much of our work is based on Dr. Lamb’s lifetime of research on these t-cells. He was the first to describe them as being associated with better survival outcomes back in the 1990s.